Quantification of hepatitis B surface antigen and e antigen: Correlation between Elecsys and Architect assays

Journal of Viral Hepatitis

Volumn 20, Issue 6, 2013, Pages 422-429

  Zhou, B ^a   Liu, M ^a   Lv, G ^a   Zheng, H ^a   Wang, Y ^a   Sun, J ^a   Hou, J ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

comparison; hepatitis B e antigen; hepatitis B surface antigen; quantification

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS E ANTIGEN; HEPATITIS E SURFACE ANTIGEN; UNCLASSIFIED DRUG;

ARCHITECT ASSAY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECSYS ASSAY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; PHYLOGENY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SEROLOGY;

ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PHYLOGENY; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; THYMIDINE;

EID: 84877580752     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12044     Document Type: Article

References (23)

1. Blumberg BS, Alter HJ, Visnich S,. A "new" antigen in leukemia sera. JAMA 1965; 191: 541-546.
2. Blumberg BS, Sutnick AI, London WT,. Hepatitis and leukemia: their relation to Australia antigen. Bull N Y Acad Med 1968; 44 (12): 1566-1586.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
4. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
5. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44 (3): 675-684.
6. Sonneveld MJ, Rijckborst V, Boucher CA, et al,. A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol 2011; 51 (3): 175-178.
7. Thompson AJ, Nguyen T, Iser D, et al,. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51 (6): 1933-1944.
8. Liaw YF,. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 54 (2): E1-9.
9. Moucari R, Mackiewicz V, Lada O, et al,. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49 (4): 1151-1157.
10. Ma H, Yang RF, Wei L,. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010; 25 (9): 1498-1506.
11. Lee JM, Ahn SH, Kim HS, et al,. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53 (5): 1486-1493.
12. Brunetto MR, Moriconi F, Bonino F, et al,. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49 (4): 1141-1150.
13. Yu ML, Lee CM, Chuang WL, et al,. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010; 202 (1): 86-92.
14. Marrone A, Zampino R, Luongo G, Utili R, Karayiannis P, Ruggiero G,. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology 2003; 46 (4): 222-226.
15. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373 (9663): 582-592.
16. Liaw YF, Lau GK, Kao JH, Gane E,. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55 (10): 2727-2734.
17. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C,. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993; 18 (6): 1306-1312.
18. Fried MW, Piratvisuth T, Lau GK, et al,. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47 (2): 428-434.
19. Zhang X, Lin SM, Ye F, et al,. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients. J Viral Hepat 2011; 18 (7): e184-190.
20. Wursthorn K, Jaroszewicz J, Zacher BJ, et al,. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011; 50 (4): 292-296.
21. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H,. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol 2003; 41 (1): 135-143.
22. Weber B,. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. Expert Rev Mol Diagn 2005; 5 (1): 75-91.
23. Bland JM, Altman DG,. Comparing two methods of clinical measurement: a personal history. Int J Epidemiol 1995; 24 (Suppl 1): S7-S14.